Navigation Links
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus

ainful and swollen joints, unexplained fever, skin rash, and kidney problems. Lupus can lead to arthritis, kidney failure, heart and lung inflammation, central nervous system abnormalities, inflammation of the blood vessels, and blood disorders. For more information on lupus, visit the Lupus Foundation of America at www.lupus.org, the European Lupus Erythematosus Federation at www.elef.rheumanet.org, or the National Institute of Arthritis and Musculoskeletal and Skin Diseases at www.niams.nih.gov.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. The Company's primary focus is rapid progress toward the commercialization of its two lead compounds, Albuferon for hepatitis C and LymphoStat-B for lupus -- both of which are in Phase 3 clinical trials.

In June 2006, HGS announced that the U.S. government exercised its option under an existing contract to purchase 20,000 doses of ABthrax(TM) for the treatment of anthrax disease. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of hematologic and solid malignancies, in addition to an antibody to the CCR5 receptor for the treatment of HIV/AIDS.

For more information about HGS, visit www.hgsi.com. For more information on LymphoStat-B, visit www.hgsi.com/products/LSB.html. Health professionals or patients interested in LymphoStat-B clinical trials or other studies involving HGS products may inquire via the "Conta
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
9. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
Post Your Comments:
(Date:12/15/2009)... Harvard medical expert internationally recognized as a leading ... decision last month to suspend Doug Barron for ... having the medical condition hypogonadism and ... unfair and discriminatory." ,, Hypogonadism is ... often referred to informally as Low T ...
(Date:12/15/2009)... -- Fenwal Inc., a global medical technology company ... availability, announced today that the U.S. Food and ... InterSol ® platelet additive solution. Fenwal ... specialized product used in combination with human plasma ... used to prevent or treat bleeding. ,, InterSol ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new market ... ,, Boehringer Ingelheim GmbH: PharmaVitae Profile ... Introduction ,, This analysis examines the ... in the Rx pharmaceutical sector. The profile ... and assessment of financial performance, with 1-6 ...
Breaking Medicine Technology:Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Heart Attacks Less Often Fatal Today 49550 1Heart Attacks Less Often Fatal Today 49550 2Heart Attacks Less Often Fatal Today 49550 3EUROPACE raises remote monitoring profile 49546 1EUROPACE raises remote monitoring profile 49546 2EUROPACE raises remote monitoring profile 49546 3Governor Rendell Discusses Impact of Budget on Services for Families of Children With Autism 49543 1Governor Rendell Discusses Impact of Budget on Services for Families of Children With Autism 49543 2
... 28 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) ... II field testing of its,anti-cancer drug, Rh-Apo2L. The ... intended to be a new drug therapy using ... is designed as a highly-targeted,therapy with direct function ...
... Initiate Phase III Program in First Half of ... Inc. (Nasdaq: IDEV ) today announced positive ... patients with acromegaly, a,disorder characterized by excessive blood ... factor 1 (IGF-1). The implant utilizes the Company,s,patented ...
Other Medicine Technology:Aida Announces Completion of Anti-Cancer Drug Phase Two Testing 2Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 2Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 3Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 4Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 5
(Date:12/15/2009)... Dec. 15 The failure of the ... to cut costs, much less the more effective ... the latest example of how big industry controls ... "The proposed drug amendment by Senator Dorgan (D-ND) ... Obama,s campaign pledge to allow Medicare to directly ...
(Date:12/15/2009)... -- Palo Alto Networks(TM), the network security company, ... PA-4000 Series next-generation firewalls for accurate threat prevention ... and control over applications such as peer-to-peer file ... university with eight facilities on five campuses. The ... number of academic schools and institutions throughout Japan. ...
(Date:12/15/2009)... couples of reproductive age were evaluated, Italian study found ... of children born with cystic fibrosis decreases when screening ... increases, a new study finds. , CF neonatal screening ... for many years. Since the 1990s, the area has ... infants born with CF. , Two different CF carrier ...
(Date:12/15/2009)... not delivered ,, WASHINGTON, Dec. 15 /PRNewswire-USNewswire/ ... ensure that healthcare reform does not override the ... companies in 37 states. ,, Prostate cancer screening ... population and individuals who are identifiable as high ... have a family history of prostate cancer. The ...
(Date:12/15/2009)... 15 Patient advocate ... Members of Congress that, "it doesn,t matter whether there,s ... - without a public option - give government authority ... also fund a new social agenda by shifting billions ... groups, newly arriving immigrants, and local politicians." ...
Breaking Medicine News(10 mins):Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 3Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2
... ALBUQUERQUE, N.M., Sept. 22 Biomoda, Inc.,(OTC Bulletin ... diagnostics company, expanded its intellectual property portfolio,with approval ... its Trademarks,CyDx(R) and CyPath(R)., "We are pleased ... for,our product portfolio," said John Cousins, Biomoda president. ...
... A study appearing in the Sept. 18 issue of ... among individuals with no colorectal neoplasia (abnormal growths) on initial ... low. The data provides support for rescreening at an interval ... , "This research is very significant as it is the ...
... radiosurgery (SRS) and whole brain radiation therapy (WBRT) for ... twice the risk of developing learning and memory problems ... research from The University of Texas M. D. Anderson ... randomized trial were presented at today,s 50th annual meeting ...
... Sept. 22 Stern + Associates (S+A), the,rapidly ... in central New Jersey with offices in Cambridge,Mass., ... roster: Biotest,Diagnostics Corporation and the Pain Control product ... addition, S+A expanded its public relations,programming for Bracco ...
... Johnson & Johnson, Ernst & Young, and,Kaplan Eduneering ... AdvaMed 2008,s list of,sponsors includes industry leaders, consulting ... the Ontario Ministry of Economic,Development & Trade (MEDT) ... number of sponsors increased this year by 52% ...
... with Social Security Disability Insurance as population ages; though disability ... , ... Belleville, Ill.(Vocus) September 22, ... retirement age, an echoing wave of the working population is ...
Other Medicine News:Health News:U.S. Patent Office Grants Biomoda Registration for Trademarks 2Health News:Risk of colorectal cancer extremely low 5 years after a normal colonoscopy screening 2Health News:Whole brain radiation increases risk of learning and memory problems in cancer patients 2Health News:Whole brain radiation increases risk of learning and memory problems in cancer patients 3Health News:Stern + Associates Signs New Clients to Health Care Practice 2Health News:AdvaMed 2008 Sponsor Participation Increases by 52% 2Health News:AdvaMed 2008 Sponsor Participation Increases by 52% 3Health News:AdvaMed 2008 Sponsor Participation Increases by 52% 4Health News:Baby Boomers' Aging Wave Affects Social Security Disability Program 2Health News:Baby Boomers' Aging Wave Affects Social Security Disability Program 3Health News:Baby Boomers' Aging Wave Affects Social Security Disability Program 4Health News:Baby Boomers' Aging Wave Affects Social Security Disability Program 5
The HearTwave system is the original stand-alone Microvolt T-Wave Alternans (MTWA) testing platform....
... trabeculum provides the highest magnification of ANY gonioscopy ... treating the trabecular meshwork. One 62° mirror ... angle while the central portion of the lens ... for signs of glaucoma and other central retinal ...
The Mid Field 30° lens has a bi-concave design to provide a wider field of view with a 30 degree offset image....
... AFX Lens is a direct ... in an air-filled eye. In ... a primary air-fluid exchange vitrectomy ... sutureless design make it well ...
Medicine Products: